Diversity of and initiatives for hypertension management in Asia—Why we need the HOPE Asia Network

Kazuomi Kario; Yook Chin Chia; Apichard Sukonthasarn; Yuda Turana; Jinho Shin; Chen Huan Chen; Peera Buranakitjaroen; Jennifer Nailes; Satoshi Hoshide; Saulat Siddique; Jorge Sison; Arieska Ann Soenarta; Guru Prasad Sogunuru; Jam Chin Tay; Boon Wee Teo; Yu Qing Zhang; Sungha Park; Huynh Van Minh; Naoko Tomitani; Tomoyuki Kabutoya; Narsingh Verma; Tzung Dau Wang; Ji Guang Wang

doi:10.1111/jch.13733

Diversity of and initiatives for hypertension management in Asia—Why we need the HOPE Asia Network

Kazuomi Kario, Yook Chin Chia, Apichard Sukonthasarn, Yuda Turana, Jinho Shin, Chen Huan Chen, Peera Buranakitjaroen, Jennifer Nailes, Satoshi Hoshide, Saulat Siddique, Jorge Sison, Arieska Ann Soenarta, Guru Prasad Sogunuru, Jam Chin Tay, Boon Wee Teo, Yu Qing Zhang, Sungha Park, Huynh Van Minh, Naoko Tomitani, Tomoyuki KabutoyaNarsingh Verma, Tzung Dau Wang, Ji Guang Wang

Department of Internal Medicine

Research output: Contribution to journal › Review article › peer-review

28 Citations (Scopus)

Abstract

The Hypertension Cardiovascular Outcome Prevention and Evidence in Asia (HOPE Asia) Network was set up to improve the management of hypertension in Asia with the ultimate goal of achieving “zero” cardiovascular events. Asia is a diverse continent, and the prevalence of hypertension has increased over the last 30 years. There are a number of Asia-specific features of hypertension and hypertension-related cardiovascular complications, which means that a region-specific approach is needed. White-coat hypertension will become more of an issue over time as Asian populations age, and masked hypertension is more prevalent in Asian than in Western countries. Identifying and treating masked hypertension is important to reduce cardiovascular risk. Abnormal patterns of blood pressure (BP) variability common in Asia include exaggerated early morning BP surge and nocturnal hypertension. These are also important cardiovascular risk factors that need to be managed. Home blood pressure monitoring (HBPM) is an important tool for detecting white-coat and masked hypertension, and monitoring BP variability, and practices in Asia are variable. Use of HBPM is important given the Asia-specific features of hypertension, and strategies are needed to improve and standardize HBPM usage. Development of HBPM devices capable of measuring nocturnal BP along with other information and communication technology-based strategies are key developments in the widespread implementation of anticipation medicine strategies to detect and prevent cardiovascular events in patients with hypertension. Region-wide differences in hypertension prevalence, control, and management practices in Asia highlight the importance of information sharing to facilitate best practices.

Original language	English
Pages (from-to)	331-343
Number of pages	13
Journal	Journal of Clinical Hypertension
Volume	22
Issue number	3
DOIs	https://doi.org/10.1111/jch.13733
Publication status	Published - 2020 Mar 1

Bibliographical note

Funding Information:
Medical writing assistance was provided by Nicola Ryan, independent medical writer. Editorial assistance was provided by Ayako Okura, Jichi Medical University.

Funding Information:
K Kario received research grants from Omron Healthcare, Fukuda Denshi, A&D, Pfizer Japan, and honoraria from Omron Healthcare. S Park has received honoraria from Pfizer, Daiichi Sankyo, Takeda, Daewon pharmaceutical company, Boryung pharmaceutical company, and Servier. S Siddique has received honoraria from Bayer, Novartis, Pfizer, ICI, and Servier; and travel, accommodation, and conference registration support from Atco Pharmaceutical, Highnoon Laboratories, Horizon Pharma, ICI, Pfizer, and CCL. YC Chia has received honoraria and sponsorship to attend conferences and CME seminars from Abbott, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Menarini, Merck Sharp & Dohme, Novartis, Orient Europharma, Pfizer, and Sanofi; and a research grant from Pfizer. J Nailes has received research grants from Pfizer. J Shin has received honoraria and sponsorship to attend seminars from Daiichi Sankyo, Takeda, Menarini, MSD, Bristol‐Myers Squibb, and Sanofi. CH Chen has served as an advisor or consultant for Novartis Pharmaceuticals Corporation; has served as a speaker or a member of a speakers bureau for AstraZeneca; Pfizer Inc; Bayer AG; Bristol‐Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc; Daiichi Sankyo, Inc; Novartis Pharmaceuticals Corporation; SERVIER; Merck & Co., Inc; Sanofi; TAKEDA Pharmaceuticals International; and has received grants for clinical research from Microlife Co., Ltd. J Sison has received honoraria from Pfizer, AstraZeneca, AmGen, Boehringer Ingelheim, and Novartis. GP Sogunuru has received a research grant related to hypertension monitoring and treatment from Pfizer. JG Wang has received research grants from Bayer, Merck Sharp & Dohme, Pfizer, and Phillips; and lecture and consulting fees from Bayer, Daiichi Sankyo, Merck Sharp & Dohme, Pfizer, Servier, and Takeda. TD Wang has received honoraria from Abbott, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Medtronic, Menarini, Novartis, Omron, Pfizer, Sanofi, and Servier. Y Zhang has received research grants from Bayer, Novartis, and Shuanghe; and lecture fees from Bayer, Daiichi Sankyo, Novartis, Pfizer, Sanofi, Servier, and Takeda. All other authors report no potential conflicts of interest in relation to this article.

Publisher Copyright:
© 2019 Wiley Periodicals, Inc.

All Science Journal Classification (ASJC) codes

Internal Medicine
Endocrinology, Diabetes and Metabolism
Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/jch.13733

Cite this

Kario, K., Chia, Y. C., Sukonthasarn, A., Turana, Y., Shin, J., Chen, C. H., Buranakitjaroen, P., Nailes, J., Hoshide, S., Siddique, S., Sison, J., Soenarta, A. A., Sogunuru, G. P., Tay, J. C., Teo, B. W., Zhang, Y. Q., Park, S., Minh, H. V., Tomitani, N., ... Wang, J. G. (2020). Diversity of and initiatives for hypertension management in Asia—Why we need the HOPE Asia Network. Journal of Clinical Hypertension, 22(3), 331-343. https://doi.org/10.1111/jch.13733

@article{7002d607a22a40d0be3a2c8991181180,

title = "Diversity of and initiatives for hypertension management in Asia—Why we need the HOPE Asia Network",

abstract = "The Hypertension Cardiovascular Outcome Prevention and Evidence in Asia (HOPE Asia) Network was set up to improve the management of hypertension in Asia with the ultimate goal of achieving “zero” cardiovascular events. Asia is a diverse continent, and the prevalence of hypertension has increased over the last 30 years. There are a number of Asia-specific features of hypertension and hypertension-related cardiovascular complications, which means that a region-specific approach is needed. White-coat hypertension will become more of an issue over time as Asian populations age, and masked hypertension is more prevalent in Asian than in Western countries. Identifying and treating masked hypertension is important to reduce cardiovascular risk. Abnormal patterns of blood pressure (BP) variability common in Asia include exaggerated early morning BP surge and nocturnal hypertension. These are also important cardiovascular risk factors that need to be managed. Home blood pressure monitoring (HBPM) is an important tool for detecting white-coat and masked hypertension, and monitoring BP variability, and practices in Asia are variable. Use of HBPM is important given the Asia-specific features of hypertension, and strategies are needed to improve and standardize HBPM usage. Development of HBPM devices capable of measuring nocturnal BP along with other information and communication technology-based strategies are key developments in the widespread implementation of anticipation medicine strategies to detect and prevent cardiovascular events in patients with hypertension. Region-wide differences in hypertension prevalence, control, and management practices in Asia highlight the importance of information sharing to facilitate best practices.",

author = "Kazuomi Kario and Chia, {Yook Chin} and Apichard Sukonthasarn and Yuda Turana and Jinho Shin and Chen, {Chen Huan} and Peera Buranakitjaroen and Jennifer Nailes and Satoshi Hoshide and Saulat Siddique and Jorge Sison and Soenarta, {Arieska Ann} and Sogunuru, {Guru Prasad} and Tay, {Jam Chin} and Teo, {Boon Wee} and Zhang, {Yu Qing} and Sungha Park and Minh, {Huynh Van} and Naoko Tomitani and Tomoyuki Kabutoya and Narsingh Verma and Wang, {Tzung Dau} and Wang, {Ji Guang}",

note = "Funding Information: Medical writing assistance was provided by Nicola Ryan, independent medical writer. Editorial assistance was provided by Ayako Okura, Jichi Medical University. Funding Information: K Kario received research grants from Omron Healthcare, Fukuda Denshi, A&D, Pfizer Japan, and honoraria from Omron Healthcare. S Park has received honoraria from Pfizer, Daiichi Sankyo, Takeda, Daewon pharmaceutical company, Boryung pharmaceutical company, and Servier. S Siddique has received honoraria from Bayer, Novartis, Pfizer, ICI, and Servier; and travel, accommodation, and conference registration support from Atco Pharmaceutical, Highnoon Laboratories, Horizon Pharma, ICI, Pfizer, and CCL. YC Chia has received honoraria and sponsorship to attend conferences and CME seminars from Abbott, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Menarini, Merck Sharp & Dohme, Novartis, Orient Europharma, Pfizer, and Sanofi; and a research grant from Pfizer. J Nailes has received research grants from Pfizer. J Shin has received honoraria and sponsorship to attend seminars from Daiichi Sankyo, Takeda, Menarini, MSD, Bristol‐Myers Squibb, and Sanofi. CH Chen has served as an advisor or consultant for Novartis Pharmaceuticals Corporation; has served as a speaker or a member of a speakers bureau for AstraZeneca; Pfizer Inc; Bayer AG; Bristol‐Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc; Daiichi Sankyo, Inc; Novartis Pharmaceuticals Corporation; SERVIER; Merck & Co., Inc; Sanofi; TAKEDA Pharmaceuticals International; and has received grants for clinical research from Microlife Co., Ltd. J Sison has received honoraria from Pfizer, AstraZeneca, AmGen, Boehringer Ingelheim, and Novartis. GP Sogunuru has received a research grant related to hypertension monitoring and treatment from Pfizer. JG Wang has received research grants from Bayer, Merck Sharp & Dohme, Pfizer, and Phillips; and lecture and consulting fees from Bayer, Daiichi Sankyo, Merck Sharp & Dohme, Pfizer, Servier, and Takeda. TD Wang has received honoraria from Abbott, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Medtronic, Menarini, Novartis, Omron, Pfizer, Sanofi, and Servier. Y Zhang has received research grants from Bayer, Novartis, and Shuanghe; and lecture fees from Bayer, Daiichi Sankyo, Novartis, Pfizer, Sanofi, Servier, and Takeda. All other authors report no potential conflicts of interest in relation to this article. Publisher Copyright: {\textcopyright} 2019 Wiley Periodicals, Inc.",

year = "2020",

month = mar,

day = "1",

doi = "10.1111/jch.13733",

language = "English",

volume = "22",

pages = "331--343",

journal = "Journal of Clinical Hypertension",

issn = "1524-6175",

publisher = "Wiley-Blackwell",

number = "3",

}

Kario, K, Chia, YC, Sukonthasarn, A, Turana, Y, Shin, J, Chen, CH, Buranakitjaroen, P, Nailes, J, Hoshide, S, Siddique, S, Sison, J, Soenarta, AA, Sogunuru, GP, Tay, JC, Teo, BW, Zhang, YQ, Park, S, Minh, HV, Tomitani, N, Kabutoya, T, Verma, N, Wang, TD & Wang, JG 2020, 'Diversity of and initiatives for hypertension management in Asia—Why we need the HOPE Asia Network', Journal of Clinical Hypertension, vol. 22, no. 3, pp. 331-343. https://doi.org/10.1111/jch.13733

TY - JOUR

T1 - Diversity of and initiatives for hypertension management in Asia—Why we need the HOPE Asia Network

AU - Kario, Kazuomi

AU - Chia, Yook Chin

AU - Sukonthasarn, Apichard

AU - Turana, Yuda

AU - Shin, Jinho

AU - Chen, Chen Huan

AU - Buranakitjaroen, Peera

AU - Nailes, Jennifer

AU - Hoshide, Satoshi

AU - Siddique, Saulat

AU - Sison, Jorge

AU - Soenarta, Arieska Ann

AU - Sogunuru, Guru Prasad

AU - Tay, Jam Chin

AU - Teo, Boon Wee

AU - Zhang, Yu Qing

AU - Park, Sungha

AU - Minh, Huynh Van

AU - Tomitani, Naoko

AU - Kabutoya, Tomoyuki

AU - Verma, Narsingh

AU - Wang, Tzung Dau

AU - Wang, Ji Guang

N1 - Funding Information: Medical writing assistance was provided by Nicola Ryan, independent medical writer. Editorial assistance was provided by Ayako Okura, Jichi Medical University. Funding Information: K Kario received research grants from Omron Healthcare, Fukuda Denshi, A&D, Pfizer Japan, and honoraria from Omron Healthcare. S Park has received honoraria from Pfizer, Daiichi Sankyo, Takeda, Daewon pharmaceutical company, Boryung pharmaceutical company, and Servier. S Siddique has received honoraria from Bayer, Novartis, Pfizer, ICI, and Servier; and travel, accommodation, and conference registration support from Atco Pharmaceutical, Highnoon Laboratories, Horizon Pharma, ICI, Pfizer, and CCL. YC Chia has received honoraria and sponsorship to attend conferences and CME seminars from Abbott, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Menarini, Merck Sharp & Dohme, Novartis, Orient Europharma, Pfizer, and Sanofi; and a research grant from Pfizer. J Nailes has received research grants from Pfizer. J Shin has received honoraria and sponsorship to attend seminars from Daiichi Sankyo, Takeda, Menarini, MSD, Bristol‐Myers Squibb, and Sanofi. CH Chen has served as an advisor or consultant for Novartis Pharmaceuticals Corporation; has served as a speaker or a member of a speakers bureau for AstraZeneca; Pfizer Inc; Bayer AG; Bristol‐Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc; Daiichi Sankyo, Inc; Novartis Pharmaceuticals Corporation; SERVIER; Merck & Co., Inc; Sanofi; TAKEDA Pharmaceuticals International; and has received grants for clinical research from Microlife Co., Ltd. J Sison has received honoraria from Pfizer, AstraZeneca, AmGen, Boehringer Ingelheim, and Novartis. GP Sogunuru has received a research grant related to hypertension monitoring and treatment from Pfizer. JG Wang has received research grants from Bayer, Merck Sharp & Dohme, Pfizer, and Phillips; and lecture and consulting fees from Bayer, Daiichi Sankyo, Merck Sharp & Dohme, Pfizer, Servier, and Takeda. TD Wang has received honoraria from Abbott, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Medtronic, Menarini, Novartis, Omron, Pfizer, Sanofi, and Servier. Y Zhang has received research grants from Bayer, Novartis, and Shuanghe; and lecture fees from Bayer, Daiichi Sankyo, Novartis, Pfizer, Sanofi, Servier, and Takeda. All other authors report no potential conflicts of interest in relation to this article. Publisher Copyright: © 2019 Wiley Periodicals, Inc.

PY - 2020/3/1

Y1 - 2020/3/1

N2 - The Hypertension Cardiovascular Outcome Prevention and Evidence in Asia (HOPE Asia) Network was set up to improve the management of hypertension in Asia with the ultimate goal of achieving “zero” cardiovascular events. Asia is a diverse continent, and the prevalence of hypertension has increased over the last 30 years. There are a number of Asia-specific features of hypertension and hypertension-related cardiovascular complications, which means that a region-specific approach is needed. White-coat hypertension will become more of an issue over time as Asian populations age, and masked hypertension is more prevalent in Asian than in Western countries. Identifying and treating masked hypertension is important to reduce cardiovascular risk. Abnormal patterns of blood pressure (BP) variability common in Asia include exaggerated early morning BP surge and nocturnal hypertension. These are also important cardiovascular risk factors that need to be managed. Home blood pressure monitoring (HBPM) is an important tool for detecting white-coat and masked hypertension, and monitoring BP variability, and practices in Asia are variable. Use of HBPM is important given the Asia-specific features of hypertension, and strategies are needed to improve and standardize HBPM usage. Development of HBPM devices capable of measuring nocturnal BP along with other information and communication technology-based strategies are key developments in the widespread implementation of anticipation medicine strategies to detect and prevent cardiovascular events in patients with hypertension. Region-wide differences in hypertension prevalence, control, and management practices in Asia highlight the importance of information sharing to facilitate best practices.

AB - The Hypertension Cardiovascular Outcome Prevention and Evidence in Asia (HOPE Asia) Network was set up to improve the management of hypertension in Asia with the ultimate goal of achieving “zero” cardiovascular events. Asia is a diverse continent, and the prevalence of hypertension has increased over the last 30 years. There are a number of Asia-specific features of hypertension and hypertension-related cardiovascular complications, which means that a region-specific approach is needed. White-coat hypertension will become more of an issue over time as Asian populations age, and masked hypertension is more prevalent in Asian than in Western countries. Identifying and treating masked hypertension is important to reduce cardiovascular risk. Abnormal patterns of blood pressure (BP) variability common in Asia include exaggerated early morning BP surge and nocturnal hypertension. These are also important cardiovascular risk factors that need to be managed. Home blood pressure monitoring (HBPM) is an important tool for detecting white-coat and masked hypertension, and monitoring BP variability, and practices in Asia are variable. Use of HBPM is important given the Asia-specific features of hypertension, and strategies are needed to improve and standardize HBPM usage. Development of HBPM devices capable of measuring nocturnal BP along with other information and communication technology-based strategies are key developments in the widespread implementation of anticipation medicine strategies to detect and prevent cardiovascular events in patients with hypertension. Region-wide differences in hypertension prevalence, control, and management practices in Asia highlight the importance of information sharing to facilitate best practices.

UR - http://www.scopus.com/inward/record.url?scp=85075755592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075755592&partnerID=8YFLogxK

U2 - 10.1111/jch.13733

DO - 10.1111/jch.13733

M3 - Review article

C2 - 31773883

AN - SCOPUS:85075755592

SN - 1524-6175

VL - 22

SP - 331

EP - 343

JO - Journal of Clinical Hypertension

JF - Journal of Clinical Hypertension

IS - 3

ER -

Diversity of and initiatives for hypertension management in Asia—Why we need the HOPE Asia Network

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this